The effect of trimebutine on the overlap syndrome model of Guinea pigs

Zahid Hussain, Da Hyun Jung, Young Ju Lee, HyoJin Park

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common gastrointestinal (GI) disorders and these patients frequently overlap. Trimebutine has been known to be effective in controlling FD co-existing diarrhea-dominant IBS, however its effect on overlap syndrome (OS) patients has not been reported. Therefore, we investigated the effect of trimebutine on the model of OS in Guinea pigs. Methods: Male Guinea pigs were used to evaluate the effects of trimebutine in corticotropin-releasing factor (CRF) induced OS model. Different doses (3, 10, and 30 mg/kg) of trimebutine were administered orally and incubated for 1 hour. The next treatment of 10 μg/kg of CRF was intraperitoneally injected and stabilized for 30 minutes. Subsequently, intragastric 3 mL charcoal mix was administered, incubated for 10 minutes and the upper GI transit analyzed. Colonic transits were assessed after the same order and concentrations of trimebutine and CRF treatment by fecal pellet output assay. Results: Different concentrations (1, 3, and 10 μg/kg) of rat/human CRF peptides was tested to establish the OS model in Guinea pigs. CRF 10 μg/kg was the most effective dose in the experimental OS model of Guinea pigs. Trimebutine (3, 10, and 30 mg/kg) treatment significantly reversed the upper and lower GI transit of CRF induced OS model. Trimebutine significantly increased upper GI transit while it reduced fecal pellet output in the CRF induced OS model. Conclusions: Trimebutine has been demonstrated to be effective on both upper and lower GI motor function in peripheral CRF induced OS model. Therefore, trimebutine might be an effective drug for the treatment of OS between FD and IBS patients.

Original languageEnglish
Pages (from-to)669-675
Number of pages7
JournalJournal of Neurogastroenterology and Motility
Volume24
Issue number4
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

Trimebutine
Corticotropin-Releasing Hormone
Guinea Pigs
Gastrointestinal Transit
Irritable Bowel Syndrome
Dyspepsia
Charcoal
Therapeutics
Diarrhea

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Gastroenterology

Cite this

Hussain, Zahid ; Jung, Da Hyun ; Lee, Young Ju ; Park, HyoJin. / The effect of trimebutine on the overlap syndrome model of Guinea pigs. In: Journal of Neurogastroenterology and Motility. 2018 ; Vol. 24, No. 4. pp. 669-675.
@article{59175246f58b4cd1b1cc7ecd3b8986d1,
title = "The effect of trimebutine on the overlap syndrome model of Guinea pigs",
abstract = "Background/Aims: Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common gastrointestinal (GI) disorders and these patients frequently overlap. Trimebutine has been known to be effective in controlling FD co-existing diarrhea-dominant IBS, however its effect on overlap syndrome (OS) patients has not been reported. Therefore, we investigated the effect of trimebutine on the model of OS in Guinea pigs. Methods: Male Guinea pigs were used to evaluate the effects of trimebutine in corticotropin-releasing factor (CRF) induced OS model. Different doses (3, 10, and 30 mg/kg) of trimebutine were administered orally and incubated for 1 hour. The next treatment of 10 μg/kg of CRF was intraperitoneally injected and stabilized for 30 minutes. Subsequently, intragastric 3 mL charcoal mix was administered, incubated for 10 minutes and the upper GI transit analyzed. Colonic transits were assessed after the same order and concentrations of trimebutine and CRF treatment by fecal pellet output assay. Results: Different concentrations (1, 3, and 10 μg/kg) of rat/human CRF peptides was tested to establish the OS model in Guinea pigs. CRF 10 μg/kg was the most effective dose in the experimental OS model of Guinea pigs. Trimebutine (3, 10, and 30 mg/kg) treatment significantly reversed the upper and lower GI transit of CRF induced OS model. Trimebutine significantly increased upper GI transit while it reduced fecal pellet output in the CRF induced OS model. Conclusions: Trimebutine has been demonstrated to be effective on both upper and lower GI motor function in peripheral CRF induced OS model. Therefore, trimebutine might be an effective drug for the treatment of OS between FD and IBS patients.",
author = "Zahid Hussain and Jung, {Da Hyun} and Lee, {Young Ju} and HyoJin Park",
year = "2018",
month = "10",
day = "1",
doi = "10.5056/jnm18049",
language = "English",
volume = "24",
pages = "669--675",
journal = "Journal of Neurogastroenterology and Motility",
issn = "2093-0879",
publisher = "Korean Society of Neurogastroenterology and Motility",
number = "4",

}

The effect of trimebutine on the overlap syndrome model of Guinea pigs. / Hussain, Zahid; Jung, Da Hyun; Lee, Young Ju; Park, HyoJin.

In: Journal of Neurogastroenterology and Motility, Vol. 24, No. 4, 01.10.2018, p. 669-675.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of trimebutine on the overlap syndrome model of Guinea pigs

AU - Hussain, Zahid

AU - Jung, Da Hyun

AU - Lee, Young Ju

AU - Park, HyoJin

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background/Aims: Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common gastrointestinal (GI) disorders and these patients frequently overlap. Trimebutine has been known to be effective in controlling FD co-existing diarrhea-dominant IBS, however its effect on overlap syndrome (OS) patients has not been reported. Therefore, we investigated the effect of trimebutine on the model of OS in Guinea pigs. Methods: Male Guinea pigs were used to evaluate the effects of trimebutine in corticotropin-releasing factor (CRF) induced OS model. Different doses (3, 10, and 30 mg/kg) of trimebutine were administered orally and incubated for 1 hour. The next treatment of 10 μg/kg of CRF was intraperitoneally injected and stabilized for 30 minutes. Subsequently, intragastric 3 mL charcoal mix was administered, incubated for 10 minutes and the upper GI transit analyzed. Colonic transits were assessed after the same order and concentrations of trimebutine and CRF treatment by fecal pellet output assay. Results: Different concentrations (1, 3, and 10 μg/kg) of rat/human CRF peptides was tested to establish the OS model in Guinea pigs. CRF 10 μg/kg was the most effective dose in the experimental OS model of Guinea pigs. Trimebutine (3, 10, and 30 mg/kg) treatment significantly reversed the upper and lower GI transit of CRF induced OS model. Trimebutine significantly increased upper GI transit while it reduced fecal pellet output in the CRF induced OS model. Conclusions: Trimebutine has been demonstrated to be effective on both upper and lower GI motor function in peripheral CRF induced OS model. Therefore, trimebutine might be an effective drug for the treatment of OS between FD and IBS patients.

AB - Background/Aims: Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common gastrointestinal (GI) disorders and these patients frequently overlap. Trimebutine has been known to be effective in controlling FD co-existing diarrhea-dominant IBS, however its effect on overlap syndrome (OS) patients has not been reported. Therefore, we investigated the effect of trimebutine on the model of OS in Guinea pigs. Methods: Male Guinea pigs were used to evaluate the effects of trimebutine in corticotropin-releasing factor (CRF) induced OS model. Different doses (3, 10, and 30 mg/kg) of trimebutine were administered orally and incubated for 1 hour. The next treatment of 10 μg/kg of CRF was intraperitoneally injected and stabilized for 30 minutes. Subsequently, intragastric 3 mL charcoal mix was administered, incubated for 10 minutes and the upper GI transit analyzed. Colonic transits were assessed after the same order and concentrations of trimebutine and CRF treatment by fecal pellet output assay. Results: Different concentrations (1, 3, and 10 μg/kg) of rat/human CRF peptides was tested to establish the OS model in Guinea pigs. CRF 10 μg/kg was the most effective dose in the experimental OS model of Guinea pigs. Trimebutine (3, 10, and 30 mg/kg) treatment significantly reversed the upper and lower GI transit of CRF induced OS model. Trimebutine significantly increased upper GI transit while it reduced fecal pellet output in the CRF induced OS model. Conclusions: Trimebutine has been demonstrated to be effective on both upper and lower GI motor function in peripheral CRF induced OS model. Therefore, trimebutine might be an effective drug for the treatment of OS between FD and IBS patients.

UR - http://www.scopus.com/inward/record.url?scp=85054612629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054612629&partnerID=8YFLogxK

U2 - 10.5056/jnm18049

DO - 10.5056/jnm18049

M3 - Article

VL - 24

SP - 669

EP - 675

JO - Journal of Neurogastroenterology and Motility

JF - Journal of Neurogastroenterology and Motility

SN - 2093-0879

IS - 4

ER -